After-hours movers: Ambarella, HP fall following results and outlook

After-Hours Stock Movers:

FibroGen, Inc. (NASDAQ:) 17% LOWER; announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) on background systemic corticosteroids. The study did not meet the primary endpoint of change in the North Star Ambulatory Assessment (NSAA) total score from baseline to week 52 (placebo-corrected mean difference -0.528 points; 95% CI -2.308 to 1.251; p=0.5553). Secondary endpoints measured by change from baseline at week 52 in 4-stair climb velocity, 10-meter walk/run test, time to stand, time to loss of ambulation, and proportion of patients with greater than 10 seconds in the 10-meter walk/run test were also not met.

Ambarella (NASDAQ:) 15% LOWER; Q2 EPS of ($0.15), $0.06 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $62.1 million versus the consensus estimate of $62.02M. Ambarella sees Q3 2024 revenue of $50M plus or minus 4%., versus the consensus of $67.6M.

Box Inc (NYSE:) 7% LOWER; Q2 EPS of $0.36, $0.01 better than the analyst estimate of $0.35. Revenue for the quarter came in at $261.43M versus the consensus estimate of $261.32M. Box sees Q3 2024 EPS of $0.37-$0.38. Box sees Q3 2024 revenue of $261-263M.

HP Inc. (NYSE:) 5% LOWER; Q3 EPS of $0.86, in-line with the analyst estimate of $0.86. Revenue for the quarter came in at $13.2 billion versus the consensus estimate of $13.38B. HP Inc. sees Q4 2023 EPS of $0.85-$0.97, versus the consensus of $0.95. HP Inc. sees FY2023 EPS of $3.23-$3.35, versus the consensus of $3.37.

PVH Corp. (NYSE:) 2% HIGHER; Q2 EPS of $1.98, $0.23 better than the analyst estimate of $1.75. Revenue for the quarter came in at $2.21B versus the consensus estimate of $2.19B. PVH Corp. sees FY2024 EPS of $10.35, versus the consensus of $10.02. Reaffirms projected increase of 3% to 4% (increase 2% to 3% on a constant currency basis).